secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-10-13T12:10:56+00:00
Accession:  0001129928-26-000070
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Oncolytics says new pelareorep method-of-use patents extend IP protection into late 2040s
--------------------------------------------------------------------------------

- New method-of-use patent covering pelareorep as a cancer immunotherapy issued in several countries; corresponding U.S. patent expected in the near term.
- Existing manufacturing patent protection runs through 2044; company targets extension into the late 2040s via new patents.
- Three patent application families pending, including multiple method-of-use filings covering pelareorep with immunotherapies and targeted therapies.
- Company expects to convert one pending application to a USPTO Track One prioritized examination this quarter, targeting final disposition in ~12 months.
- Working with an academic partner on 'next generation' modified pelareorep; a new composition of matter patent could add up to 20 years from filing, CEO Jared Kelly said.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/0001129928-26-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/oncy-20261012.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer